Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Grail Raises $300 Million from China Investors for Early Cancer Diagnostics

publication date: May 21, 2018

Grail, a Hong Kong-US oncology diagnostics company, announced a $300 million C financing. Since early 2016, Grail has raised over $1.5 billion. The company is sequencing large populations of people -- some with cancer, some without -- to discover an early blood-based diagnostic test for cancer. Grail was spun out of Illumina, the gene sequencing company. Ally Bridge Group led the financing. Hillhouse Capital and 6 Dimensions Capital co-led the round. In 2017, Grail merged with Cirina, a Hong Kong cancer diagnostics company, which was co-founded by Dennis Lo, DM, DPhil, an early scientific leader in the field of molecular diagnostics. More details....

Stock Symbol: (NSDQ: ILMN)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital